Exelixis registers Phase 2 trial of zanzalintinib plus pembrolizumab in squamous NSCLC maintenanceNov 12Trial updateExelixispembrolizumab
HCRN withdraws phase 2 zanzalintinib trial in advanced urothelial carcinomaNov 9Trial updateExelixiszanzalintinib
Wave Life Sciences details Q3 2026 progress on WVE-006, WVE-007, WVE-008 pipelineOct 28Quarterly updateBristol Myers SquibbEli LillyUpdated
UT Southwestern registers Phase 1/2 trial pairing tegavivint with Exelixis' zanzalintinib in HCCOct 16Trial updateExelixiszanzalintinib
Exelixis registers Phase 2 trial pairing zanzalintinib with pembrolizumab in NSCLCSep 29Trial updateExelixispembrolizumab
Exelixis registers Phase 1 pediatric trial of zanzalintinib in solid tumorsAug 19Trial updateExelixiszanzalintinib
Exelixis registers Phase 3 STELLAR-316 trial of zanzalintinib in colorectal cancer MRDAug 6Trial updateExelixisMerck & Co., Inc.
Exelixis Q2 2026 results detail zanzalintinib pipeline progress, narrows guidanceAug 5Quarterly updateExelixisMerck & Co., Inc.
Dana-Farber registers Phase 2 zanzalintinib trial for rare adrenal tumors, Exelixis collaboratingJul 20Trial updateExelixiszanzalintinib